 |
|
|
| |
High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
Safia Kuriakose1, Jomy George2, Nicola Dee1, Pamela Stoll2, Brian K. Agan3, Robin L. Dewar1, Alice Pau4, Frank Maldarelli5
1Leidos Biomedical Research, Inc., Frederick, MD, USA
2National Institutes of Health (NIH) Clinical Center (CC), Bethesda, MD, USA
3Uniformed Services University of the Health Sciences, Bethesda, MD, USA
4National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
5National Cancer Institute, Frederick, MD, USA
WEBCAST - Themed Discussion: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF? - http://www.croiwebcasts.org/console/player/37220?mediaType=slideVideo&&crd_fl=1&ssmsrq=1521988681596&ctms=5000&csmsrq=1024
|
| |
|
|
|
|
|
